Browse studies

Find your next paid study

17 recruiting studies matching your filters

Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults With Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas…

Diffuse Midline Glioma (DMG)GlioblastomaRecurrent Ependymoma+5 more

Estimated

~$10 – $7,500

Sabine Mueller, MD, PhDNCT04732065

Phase 1

A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the max…

Central Nervous System NeoplasmsGlioblastomaGliosarcoma, Adult+20 more

JACOB: Joint Administration of cDNA for TP53, checkpOint Inhibition and Boost/Hypofractionated Radiation. A Phase 0/1 Study in Children With Recurrent, Progressive or Refractory CNS Malignancies.

This clinical trial is studying a drug called SGT-53 along with radiation and another drug called Nivolumab. It's for children with brain tumors that have come…

CNS MalignanciesMedulloblastoma RecurrentATRT Recurrent+4 more

Estimated

~$10 – $5,625

Children's National Research InstituteNCT07017816

Phase 1

Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express …

Central Nervous System TumorDiffuse Intrinsic Pontine GliomaDiffuse Midline Glioma+8 more

Estimated

~$10 – $6,250

Seattle Children's HospitalNCT04185038

Phase 1

Repurposing Ibrutinib for Chemo-Immunotherapy in a Phase 1b Study of Ibrutinib With Indoximod Plus Metronomic Cyclophosphamide and Etoposide for Pediatric Patients With Brain Cancer

Recent lab-based discoveries suggest that IDO (indoleamine 2,3-dioxygenase) and BTK (Bruton's tyrosine Kinase) form a closely linked metabolic checkpoint in tu…

EpendymomaMedulloblastomaGlioblastoma+1 more

Estimated

~$10 – $7,500

Theodore S. JohnsonNCT05106296